trending Market Intelligence /marketintelligence/en/news-insights/trending/AgONb5Y4RM9v_Fn86bOFCw2 content esgSubNav
In This List

Imports into EU from facility of Dr. Reddy's unit suspended

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Imports into EU from facility of Dr. Reddy's unit suspended

German regulators decided to not renew the good manufacturing practice compliance certificate of an Indian manufacturing facility operated by a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd.

The move by the Regulatory Authority of Germany follows its recent inspection of betapharm Arzneimittel GmbH's unit 2 plant in Bachupally, Hyderabad.

No products from the plant will be admissible into the European Union until the regulator revokes its noncompliance notification. Betapharm will initiate the the next inspection by inviting the German regulator.